
Rationale for Correct Answer
The correct answer is: Approved for NTRK-positive solid tumors and ROS1-positive NSCLC
Entrectinib is FDA approved for:
- NTRK-positive solid tumors without a known resistance mutation; metastatic, or where surgical resection is likely to result in severe morbidity; and that have progressed following treatment or have no satisfactory alternative therapy
- ROS1-positive metastatic NSCLC
Entrectinib is not approved for use in ALK-positive NSCLC.
Reference:
U.S. Food & Drug Administration (FDA). Oncology (Cancer) / Hematologic Malignancies Approval Notifications. Reviewed June 20, 2023. Accessed June 20, 2023. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm